Vitae Pharmaceuticals Inc (NASDAQ:VTAE) shares jumped 94% in pre-market trading after the company announced positive top-line results from its experimental psoriasis drug VTP-43742. The …
Bio Blast Pharma Ltd (NASDAQ:ORPN) announced that it has entered into definitive securities purchase agreements with two healthcare focused institutional investors providing for the …
Bio Blast Pharma Ltd (NASDAQ:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD Phase 2 six-month open-label clinical study in …
Bio Blast Pharma Ltd (NASDAQ:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare genetic diseases, today provided an update …
Bio Blast Pharma Ltd (NASDAQ:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September 30, 2015. BioBlast …
Bio Blast Pharma Ltd (NASDAQ:ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced the appointment of …
Bio Blast Pharma Ltd (NASDAQ:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it was granted a patent from the United States Patent …
Bio Blast Pharma Ltd (NASDAQ:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today …
Bio Blast Pharma Ltd (NASDAQ:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2015. BioBlast …
Oppenheimer analyst Yigal Nochomovitz maintained an Outperform rating on Bio Blast Pharma Ltd (NASDAQ:ORPN) with a price target of $32, after the company announced positive …